AstraZeneca (NYSE:AZN) says there were "no reports of opioid withdrawal" that could be...

AstraZeneca (NYSE:AZN) says there were "no reports of opioid withdrawal" that could be attributed to its Naloxegol laxative in a fourth Phase III trial. AZN and partner Nektar Therapeutics (NASDAQ:NKTR) will use the outcome to obtain decontrol of naloxegol, which is considered a Schedule II controlled substance by the DEA. With the testing demonstrating other "high-level" safety results, AstraZeneca plans to file for FDA and EU approval of Naloxegol in Q3. (PR)